Completed PHASE3 INTERVENTIONAL NCT00274014

Measure of the Long Term Influence of SPIRIVA® in Acute Respiratory Disorders

Effects of Inhaled Tiotropium Bromide on Severity of Airflow Obstruction During Long-term Treatment in Patients With Moderately Severe Copd. Impact on Severity and Incidence of Exacerbations.

Sponsor: Boehringer Ingelheim

Conditions Pulmonary Disease, Chronic Obstructive

Interventions Tiotropium

Updated 6 times since 2017 Last updated: Oct 31, 2013 Started: Oct 31, 2000 Primary completion: Oct 31, 2003 Completion: Oct 31, 2003

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Pulmonary Disease, Chronic Obstructive and is currently completed. Boehringer Ingelheim leads this study, which shows 6 recorded versions since 2000 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Oct 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Boehringer Ingelheim

Data source: Boehringer Ingelheim

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Angers, France , Annecy, France , Aubagne, France , Avrillé, France , Bois-Guillaume, France , Caluire-et-Cuire, France , Cholet, France , Châlons-en-Champagne, France , Clermont-Ferrand, France , Cornebarrieu, France and 23 more locations